Ermium Therapeutics

Developer of therapies for auto-immune inflammatory diseases

placeParis, Ile De France, France calendar_todayFounded 2019 groups9 employees language ermium.com

Innovation

1 patent family — focus: Chemistry & metallurgy; filing pace steady. Cited 43 times.

YearFilings
20221
20231
20241
20251

Investor mix

6 investors on record; lead investors include Kurma Partners, Domain Therapeutics, Idinvest Partners, Erganeo.

Investor typeCountShare
Venture capital350%
Private equity233%
Other / undisclosed117%
Coming soon